-1752957139171.webp&w=3840&q=75)
2025 NOSCM | Melanoma: Novel Advances in Immunotherapy
Overview
Dr. Sanjiv Agarwala highlighted melanoma immunotherapy progress, with long-term cures in 40–50% of metastatic cases. Nivolumab + anti-LAG-3 is effective, while some triplets failed. TILs help refractory cases. Anti-PD-1 is standard adjuvant therapy; neoadjuvant ipilimumab/nivolumab boosts event-free survival.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Sanjiv Agarwala, MD, FASCO
Date of Release
July 20th, 2025
-1755988066641.webp&w=3840&q=75)
-1755987918967.webp&w=3840&q=75)